Why Are GLP-1 Drugs 14 Times More Expensive in the U.S.?

In a recent Senate hearing, the price disparity of GLP-1 drugs in the United States compared to other countries was scrutinized. Sen. Bernie Sanders questioned Novo Nordisk’s CEO, Lars Fruergaard Jørgensen, about the staggering difference in cost for drugs like Ozempic and Wegovy in the U.S. versus other countries. These drugs, initially developed for diabetes and now widely used for weight loss, have become emblematic of the skyrocketing prices of drugs in America.

The Complexity of U.S. Drug Pricing

The crux of the issue lies in how the U.S. handles drug pricing compared to other countries. In countries like the U.K. or Germany, governments directly negotiate drug prices with pharmaceutical companies. The U.S., on the other hand, relies on a free-market system where pharmaceutical companies set the initial list price. From there, a labyrinth of negotiations, rebates, and deals with pharmacy benefit managers (PBMs) complicates the process.

“Pharmaceutical companies in the U.S. can set prices as high as the market will bear,” says Geoff Cook, CEO of Noom. “There’s very little direct negotiation compared to other parts of the world, and the result is that patients pay the price.”

- Advertisement -

The Fallout for Patients

For many patients, especially those looking to use GLP-1 drugs for weight loss rather than diabetes management, the high prices and lack of insurance coverage can lead to major health setbacks. In the U.S., weight loss medications like Wegovy and Zepbound are often excluded from insurance coverage, leaving patients to bear the full brunt of the cost.

And while pharmaceutical companies like Novo Nordisk argue that their list prices are just starting points for negotiation, for those without coverage, the list price is often the reality.

“Many of my friends and I are paying out of pocket and can’t afford $1,000 or even $500 a month,” says GLP-1 patient Michelle Turner, who has struggled with both PCOS and weight management. “It feels like a luxury, not healthcare.”

Compounded Medications

Some online wellness platforms, like Ro, Noom, and Hers, have begun offering compounded versions of semaglutide to patients. Cook says their compounded semaglutide comes from a 503B compounding pharmacy and costs around $149 per month—making it more accessible for those who can’t afford the branded versions of the drug.

However, this solution may not last long. Currently, the FDA permits the production of compounded GLP-1 medications due to a shortage of the drugs. This could change if the FDA determines that the shortage is over. “Once the shortage ends, patients could lose access to these affordable options overnight,” warns Cook.

A Complex Future for GLP-1s

As the debate over drug pricing unfolds, millions of patients wonder if affordable access to their medication will ever become a reality. Compounded medications may offer a temporary solution, but a long-term fix will likely require significant policy changes.

“We’re working with policymakers to ensure patients have affordable access to these drugs,” says Cook. “But we need systemic change to make that happen.”

Conclusion

For now, patients and advocates alike are watching Congress closely, hoping that the growing scrutiny on pharmaceutical pricing will lead to real reforms—and that the next time senators ask why GLP-1s are so much cheaper abroad, there will be a better answer.

Frequently Asked Questions

Why are GLP-1 drugs more expensive in the U.S. compared to other countries?

GLP-1 drugs are more expensive in the U.S. due to the complex system of drug pricing in the country. The U.S. relies on a free-market system, whereas other countries, such as the U.K. or Germany, directly negotiate drug prices with pharmaceutical companies.

What are pharmacy benefit managers (PBMs) and how do they impact drug pricing?

PBMs are companies that negotiate discounts with pharmaceutical companies and handle claims processing for health insurance companies. They play a significant role in determining the final price of drugs to patients. However, critics argue that PBMs prioritize their own profits over patient access and affordability.

What is a compounded version of semaglutide?

A compounded version of semaglutide is a modified version of the drug produced by a 503B compounding pharmacy. These pharmacies can produce drugs not manufactured by pharmaceutical companies and may offer more affordable options for patients.

Why may the compounded version of semaglutide not be a long-term solution?

The FDA permits the production of compounded GLP-1 medications due to a shortage of the drugs. If the shortage ends, patients could lose access to these affordable options overnight, as the FDA may determine that the compounded versions are not approved.

What changes do patients and advocates want to see in the pharmaceutical pricing system?

Patients and advocates want to see systemic changes to the pharmaceutical pricing system, including increased transparency and regulation of drug prices. They also advocate for increased government negotiation power and affordability measures to ensure that patients can access necessary medications without financial burden.